

ASX RELEASE 30 JUNE 2026

EPSILON HEALTHCARE LIMITED

TERMINATION OF PROMISSORY NOTE AND ENTRY INTO DEBT FACILITY AGREEMENT

Epsilon Healthcare Limited (ACN 614 508 039) (ASX: EPN) (**Epsilon** or the **Company**) refers to its prior ASX announcements in which the Company disclosed a \$2,000,000 promissory note entered into between the Company and Lekarna Pty Ltd (ACN 164 104 161) (**Lekarna**) (**Promissory Note**).

Lekarna is a company controlled by Epsilon's Group Chief Executive Officer and Managing Director, Mr Peter Giannopoulos.

Termination of Promissory Note

Epsilon advises that, with effect from 30 June 2026, the Company and Lekarna have agreed to terminate the Promissory Note.

As at 30 June 2026, Lekarna had advanced \$280,000 to the Company under the Promissory Note (**Advanced Amount**). The Advanced Amount (together with accrued interest of \$13,939.73 as at 30 June 2026) has been acknowledged and converted under a separate unsecured loan deed dated 30 June 2026 between the Company and Lekarna on arm's length terms (**Advanced Amount Arrangement**).

Entry into Facility Agreement

Contemporaneously with the termination of the Promissory Note and entry into the Advanced Amount Arrangement, EPN and Lekarna have also entered into a separate debt facility agreement on arm's length terms (**Facility Agreement**). The key terms of the Facility Agreement are as follows:

Term	Detail
Lender	Lekarna Pty Ltd (ACN 164 104 161)
Borrower	Epsilon Healthcare Limited (ACN 614 508 039)
Facility limit	Up to \$1,720,000
Purpose	Working capital, going concern support, and general corporate purposes
Interest rate	15% per annum on drawn amounts only
Default interest rate	2% per annum above the applicable interest rate, accruing on overdue amounts from the due date until the date of actual payment
Final repayment date	31 December 2027 (Final Repayment Date)
Security	None
Convertibility	Non-convertible (i.e. no shares, options or equity-linked rights of any kind arise from the Facility Agreement)
Interest payments	Payable quarterly in arrears

Term	Detail
Repayment	Full repayment of all outstanding principal, interest and other amounts on the Final Repayment Date
Prepayment	Permitted on 30 days' written notice (minimum prepayment of \$50,000; no prepayment penalty)

The Facility Agreement is a conventional unsecured debt facility which otherwise contains terms and conditions, including representations, undertakings and events of default, that are customary for an arrangement of its nature.

Authorisation

This announcement has been authorised for release by the Board of Directors of the Company (other than Mr Giannopoulos, who has not participated in the Board of Directors' deliberations or decision-making in respect of termination of the Promissory Note, entry into the Advanced Amount Arrangement, or entry into the Facility Agreement given his material personal interest in the subject matter).

ENDS

Alan Beasley
Chairman

For further information, please contact:
Peter Giannopoulos
Group Chief Executive Officer and Managing Director
e: corporate@epsilonhealthcare.com.au



Epsilon Healthcare Limited (ASX: EPN) – epsilonhealthcare.com.au

Epsilon Healthcare Limited (**ASX: EPN**) is an Australian based, globally active healthcare organisation. EPN operates a diversified and vertically integrated portfolio of assets, including healthcare and clinics operation, pharmaceutical contract development and manufacture, pharmacy and biotechnology therapeutic products.

